title: Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
abstract: Chronic immune thrombocytopenia (ITP) is an autoimmune disease that results in chronically low platelet counts. Treatment guidelines recommend a platelet count of at least 50,000/µl before minor surgery and at least 80,000/µl before major surgery. This retrospective analysis explored invasive non-dental procedures associated with the risk of bleeding (hemostatic challenges) among patients with chronic ITP in five phase 2/phase 3 studies of the thrombopoietin-receptor agonist, eltrombopag. Data collection for patients who underwent hemostatic challenges included demographics, study medication, timing of the procedure, platelet counts at last assessment before and first assessment after the procedure, supplemental ITP treatment, and bleeding events. Among 494 patients who participated in the studies, 87 hemostatic challenges were recorded. Median platelet counts before 44 major procedures in 32 patients were 100,000/µl and 18,500/µl among patients who received eltrombopag and placebo, respectively; before 43 minor procedures in 38 patients, median platelet counts were 82,000/µl and 20,000/µl among patients who received eltrombopag and placebo, respectively. A minority of patients required supplemental ITP treatment. Only 2 of 87 hemostatic challenges were associated with bleeding events; both patients received eltrombopag and pre-procedural platelet counts were 83,000/µl and 2000/µl. Although the number of patients who did not undergo procedures due to thrombocytopenia was not captured, these data suggest a majority of patients with chronic ITP who receive eltrombopag and experience increases in platelet counts meet current pre-procedural platelet count recommendations. The potential role of eltrombopag in supporting preparation of chronic ITP patients for surgical procedures still needs to be clinically established.
authors: Department of Pediatric Hematology/Oncology, University of Illinois College of Medicine-Peoria , Peoria, IL , USA.
authors: Michael D
authors: MD
authors: Tarantino
authors: Kalpana K
authors: KK
authors: Bakshi
authors: Andrés
authors: A
authors: Brainsky
mesh_terms: D000328:Adult; D000368:Aged; D001565:Benzoates / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects; D002908:Chronic Disease; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D019106:Postoperative Hemorrhage / Q000097:blood / Q000517:prevention & control; D011720:Pyrazoles / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013514:Surgical Procedures, Operative / Q000009:adverse effects / Q000379:methods; D013921:Thrombocytopenia / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; C520809:eltrombopag
references: Lancet. 2009 Feb 21;373(9664):641-8
references: 19231632
references: Blood Transfus. 2011 Jul;9(3):262-73
references: 21251458
references: Blood. 2011 Apr 21;117(16):4190-207
references: 21325604
references: Am J Hematol. 2004 Jul;76(3):205-13
references: 15224353
references: Blood. 2010 Jan 14;115(2):168-86
references: 19846889
references: Best Pract Res Clin Anaesthesiol. 2008 Sep;22(3):585-609
references: 18831305
references: Lancet. 2011 Jan 29;377(9763):393-402
references: 20739054
references: Ann Hematol. 2010 Dec;89(12):1185-95
references: 20842501
references: Stem Cells. 2009 Feb;27(2):424-30
references: 19038790
references: Blood. 2010 Nov 25;116(22):4639-45
references: 20688957
references: Br J Surg. 2008 Jan;95(1):1-3
references: 18165942
references: N Engl J Med. 2007 Nov 29;357(22):2237-47
references: 18046028
references: World J Surg. 1993 Mar-Apr;17(2):207-14
references: 8511915